Is there a need for novel cardiovascular risk factors?

Nephrology Dialysis Transplantation

Volumn 19, Issue 4, 2004, Pages 761-765

  von Eckardstein, Arnold ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

C reactive protein; Coronary heart disease; Fibrinogen; Homocysteine; Lipoprotein(a); Micro albuminuria; Risk factor

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SMOKING HABIT; STATISTICS; VENOUS THROMBOEMBOLISM;

ALBUMINURIA; APOLIPOPROTEINS A; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FIBRINOGEN; HOMOCYSTEINE; HUMANS; RISK ASSESSMENT;

EID: 1842523281     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh111     Document Type: Editorial

References (35)

1. Khot UN, Khot MB, Bajzer CT et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904
2. Greenland P, Knoll MD, Stamler J et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290: 891-897
3. Assmann G, Cullen P. Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-315
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
6. De Backer G, Ambrosioni E, Borch-Johnson K et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003; 24: 1601-1610
7. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003; 24: 937-945
8. Voss R, Cullen P. Schulte H, Assmann G. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002; 31: 1253-1262
9. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: A critical review of the evidence. JAMA 2000; 290: 932-940
10. Mosca L. C-reactive protein - to screen or not to screen? N Engl J Med 2002; 347: 1615-1617
11. Marcovina SM, Koschinsky ME, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent advances and future directions. Clin Chem 2003; 49: 1785-1796
12. Marcovina SM, Albers JJ, Scanu AM et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000; 46: 1956-1967
13. Kronenberg F, Neyer U, Lhotta K et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up. J Am Soc Nephrol 1999; 10: 1027-1036
14. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434-439
15. Strater R, Becker S, von Eckardstein A et al. Prospective assessment of risk factors for recurrent stroke during childhood - a 5-year follow-up study. Lancet 2002; 360: 1540-1545
16. Nowak-Gottl U, Junker R, Kreuz W et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97: 858-862
17. Shlipak MG, Simon JA, Vittinghoff E et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845-1852
18. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997; 52: 254-261
19. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003; 111: 1805-1812
20. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369
21. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: Implications for cardiovascular disease risk assessment. Clin Chem 2003; 49: 1258-1271
22. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565
23. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965
24. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979
25. Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002; 22: 1042-1045
26. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002; 288: 2015-2522
27. Clark S, Youngman LD, Sullivan J, Peto R, Collins R. Stabilization of homocysteine in unseparated blood over several days: A solution for epidemiological studies. Clin Chem 2003; 49: 518-520
28. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: The Swiss Heart study: A randomized controlled trial. JAMA 2002; 288: 973-979
29. Schnyder G, Flammer Y, Roffi M, Pin R, Hess OM. Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol 2002; 40: 1769-1776
30. Pontremoli R, Leoncini G, Ravera M et al. Microalbuminuria, cardiovascular, and renal risk in primary hypertension. J Am Soc Nephrol 2002; 13 [Suppl 3]: S169-S172
31. Parving HH, Hovind P. Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep 2002; 4: 387-393
32. Hillege HL, Fidler V, Diercks GF el al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
33. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-1997
34. Houlihan CA, Tsalamandris C, Akdeniz A, Jerums G. Albumin to creatinine ratio: A screening test with limitations. Am J Kidney Dis 2002; 39: 1183-1189
35. Derhasching U, Kittler H, Woisetschlager C, Bur A, Herkner H, Hirschl MM. Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients? Nephrol Dial Transplant 2002; 17: 81-85